首页 > 最新文献

Journal of Hepato‐Biliary‐Pancreatic Sciences最新文献

英文 中文
Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi-institutional retrospective study. 评估肝脏免疫状态指数在预测肝细胞癌患者术后预后方面的功效:一项多机构回顾性研究
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-23 DOI: 10.1002/jhbp.12070
Yuki Imaoka, Masahiro Ohira, Tsuyoshi Kobayashi, Naruhiko Honmyo, Michinori Hamaoka, Takashi Onoe, Daisuke Takei, Koichi Oishi, Tomoyuki Abe, Toshihiro Nakayama, Miho Akabane, Kazunari Sasaki, Hideki Ohdan

Background: Hepatocellular carcinoma (HCC) ranks third in cancer-related deaths globally. Despite treatment advances, high post-hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL-mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.

Methods: A retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB-4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan-Meier estimations and log-rank tests.

Results: LISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2-year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB-4 index reliabilities improved. The HISCO-HCC score, combining LISI, tumor burden score, and alpha-fetoprotein levels, enhanced prognostic accuracy.

Conclusion: LISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO-HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.

背景:肝细胞癌(HCC)在全球癌症相关死亡中排名第三。尽管治疗取得了进展,但肝切除术后的高复发率(RR),尤其是肝纤维化和丙型肝炎病毒感染,仍然是一项挑战。影响预后的关键因素包括血管侵犯和围手术期失血,从而影响肝外复发。自然杀伤(NK)细胞是通过 TRAIL 介导的途径对抗循环肿瘤细胞的关键。本研究旨在验证肝脏免疫状态指数(LISI)作为肝脏NK细胞抗肿瘤效率预测工具的有效性,尤其是在有血管侵犯的HCC患者中:方法:广岛临床肿瘤学外科研究小组(HiSCO)对 1337 例原发性 HCC 肝切除术进行了回顾性分析。临床人口学数据来自电子病历。预后指数(FIB-4、ALBI、ALICE、GNRI、APRI 和 LISI)采用接收者操作特征曲线下面积值进行评估。生存分析采用卡普兰-梅耶估计和对数秩检验:结果:LISI与其他预后指标有明显的相关性,并将患者分为具有不同总生存期(OS)和RR的风险组。LISI对2年OS和RR的预测能力更强,尤其是对有血管侵犯的患者。随着时间的延长,APRI 和 FIB-4 指数的可靠性也有所提高。HISCO-HCC评分结合了LISI、肿瘤负荷评分和甲胎蛋白水平,提高了预后准确性:结论:LISI优于现有模型,尤其是在有血管侵犯的HCC中。HISCO-HCC评分提高了预后的准确性,为HCC的免疫治疗策略和患者个体化治疗提供了指导。
{"title":"Evaluation of prognostic efficacy of liver immune status index in predicting postoperative outcomes in hepatocellular carcinoma patients: A multi-institutional retrospective study.","authors":"Yuki Imaoka, Masahiro Ohira, Tsuyoshi Kobayashi, Naruhiko Honmyo, Michinori Hamaoka, Takashi Onoe, Daisuke Takei, Koichi Oishi, Tomoyuki Abe, Toshihiro Nakayama, Miho Akabane, Kazunari Sasaki, Hideki Ohdan","doi":"10.1002/jhbp.12070","DOIUrl":"https://doi.org/10.1002/jhbp.12070","url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) ranks third in cancer-related deaths globally. Despite treatment advances, high post-hepatectomy recurrence rates (RR), especially with liver fibrosis and hepatitis C virus infection, remain challenging. Key prognostic factors include vascular invasion and perioperative blood loss, impacting extrahepatic recurrence. Natural killer (NK) cells are crucial in countering circulating tumor cells through TRAIL-mediated pathways. The aim of this study was to validate the liver immune status index (LISI) as a predictive tool for liver NK cell antitumor efficiency, particularly in HCC patients with vascular invasion.</p><p><strong>Methods: </strong>A retrospective analysis of 1337 primary HCC hepatectomies was conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO). Clinicodemographic data were extracted from electronic medical records. Prognostic indices (FIB-4, ALBI, ALICE, GNRI, APRI, and LISI) were evaluated using area under the receiver operating characteristic curve values. Survival analyses employed Kaplan-Meier estimations and log-rank tests.</p><p><strong>Results: </strong>LISI significantly correlated with other prognostic markers and stratified patients into risk groups with distinct overall survival (OS) and RR. It showed superior predictive performance for 2-year OS and RR, especially in patients with vascular invasion. Over longer periods, APRI and FIB-4 index reliabilities improved. The HISCO-HCC score, combining LISI, tumor burden score, and alpha-fetoprotein levels, enhanced prognostic accuracy.</p><p><strong>Conclusion: </strong>LISI outperformed existing models, particularly in HCC with vascular invasion. The HISCO-HCC score offers improved prognostic precision, guiding immunotherapeutic strategies and individualized patient care in HCC.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic assessment of minor papilla morphology: Predictors of successful cannulation and procedural pancreatitis risk in minor papilla endotherapy 小乳头形态的内窥镜评估:小乳头内窥镜疗法中成功插管和手术性胰腺炎风险的预测因素
IF 3 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-10 DOI: 10.1002/jhbp.12068
Yasuhiro Kuraishi, Akira Nakamura, Shohei Kondo, Takumi Yanagisawa, Ichitaro Horiuchi, Masafumi Minamisawa, Nobukazu Sasaki, Yugo Iwaya, Tadanobu Nagaya, Takeji Umemura
BackgroundWe evaluated for predictors of successful cannulation and post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in minor papilla endotherapy (MPE), emphasizing endoscopic minor papilla morphology.MethodsWe retrospectively analyzed 232 MPEs in 65 patients, assessing minor papilla morphology based on three features: bulge as “prominent” or “subtle,” mucosal appearance as “papilla‐like” resembling the main papilla or “SMT‐like” akin to a gastrointestinal submucosal tumor, and orifice visibility as “clear” or “unclear.” Cannulation success was evaluated in 65 enrolled patients, with PEP risk assessed in all 232 MPEs.ResultsMinor papilla morphology was categorized as prominent/subtle bulge in 42/23 patients, papilla‐like/SMT‐like mucosal appearance in 42/23, and clear/unclear orifice visibility in 24/41. Cannulation succeeded in 54/65 patients (83%). A papilla‐like appearance and clear orifice visibility was significantly associated with cannulation success. PEP incidence was 5.2% and predominantly mild. A papilla‐like appearance significantly decreased PEP incidence, while precutting technique and orifice dilation significantly increased PEP risk.ConclusionEvaluating minor papilla morphology may help predict cannulation success and PEP risk in MPE. A papilla‐like mucosal appearance prognosticates cannulation success and reduced PEP risk, with clear orifice visibility serving as a success predictor. These findings provide practical guidance for preprocedural planning by emphasizing the importance of minor papilla morphology evaluation.
背景我们评估了小乳头内切术(MPE)中成功插管和内镜逆行胰胆管造影术(ERCP)后胰腺炎(PEP)的预测因素,强调了内镜小乳头形态。方法我们回顾性分析了 65 位患者的 232 例 MPE,根据以下三个特征评估小乳头形态:隆起为 "突出 "或 "微小",粘膜外观为类似主乳头的 "乳头样 "或类似胃肠粘膜下肿瘤的 "SMT 样",孔口可见度为 "清晰 "或 "不清晰"。结果42/23 例患者的轻度乳头形态分为突出/微小隆起,42/23 例患者的乳头样/SMT 样粘膜外观,24/41 例患者的孔口可见度为清晰/不清晰。54/65 例患者(83%)成功进行了插管。乳头样外观和管口清晰可见与插管成功率明显相关。PEP 发生率为 5.2%,主要为轻度。乳头样外观可明显降低 PEP 发生率,而预切割技术和管口扩张则会明显增加 PEP 风险。乳头状粘膜外观预示着插管的成功率和 PEP 风险的降低,清晰的管口可见度也是预测成功率的一个指标。这些发现强调了小乳头形态评估的重要性,为术前规划提供了实用指导。
{"title":"Endoscopic assessment of minor papilla morphology: Predictors of successful cannulation and procedural pancreatitis risk in minor papilla endotherapy","authors":"Yasuhiro Kuraishi, Akira Nakamura, Shohei Kondo, Takumi Yanagisawa, Ichitaro Horiuchi, Masafumi Minamisawa, Nobukazu Sasaki, Yugo Iwaya, Tadanobu Nagaya, Takeji Umemura","doi":"10.1002/jhbp.12068","DOIUrl":"https://doi.org/10.1002/jhbp.12068","url":null,"abstract":"BackgroundWe evaluated for predictors of successful cannulation and post‐endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) in minor papilla endotherapy (MPE), emphasizing endoscopic minor papilla morphology.MethodsWe retrospectively analyzed 232 MPEs in 65 patients, assessing minor papilla morphology based on three features: bulge as “prominent” or “subtle,” mucosal appearance as “papilla‐like” resembling the main papilla or “SMT‐like” akin to a gastrointestinal submucosal tumor, and orifice visibility as “clear” or “unclear.” Cannulation success was evaluated in 65 enrolled patients, with PEP risk assessed in all 232 MPEs.ResultsMinor papilla morphology was categorized as prominent/subtle bulge in 42/23 patients, papilla‐like/SMT‐like mucosal appearance in 42/23, and clear/unclear orifice visibility in 24/41. Cannulation succeeded in 54/65 patients (83%). A papilla‐like appearance and clear orifice visibility was significantly associated with cannulation success. PEP incidence was 5.2% and predominantly mild. A papilla‐like appearance significantly decreased PEP incidence, while precutting technique and orifice dilation significantly increased PEP risk.ConclusionEvaluating minor papilla morphology may help predict cannulation success and PEP risk in MPE. A papilla‐like mucosal appearance prognosticates cannulation success and reduced PEP risk, with clear orifice visibility serving as a success predictor. These findings provide practical guidance for preprocedural planning by emphasizing the importance of minor papilla morphology evaluation.","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142213279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics and outcomes of minimally invasive surgery for congenital biliary dilatation in children aged <6 years: Comparison between children and adults. 6岁以下儿童先天性胆道扩张微创手术的特点和疗效:儿童与成人的比较。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-09-08 DOI: 10.1002/jhbp.12069
Yoichi Nakagawa, Hiroo Uchida, Chiyoe Shirota, Takahisa Tainaka, Satoshi Makita, Miwa Satomi, Akihiro Yasui, Yoko Kano, Daiki Kato, Takuya Maeda

Background/purpose: We evaluated the minimally invasive surgery for congenital biliary dilatation (CBD) in adults and children and analyzed the surgical outcomes, especially in children aged <6 years.

Methods: Characteristics and surgical outcomes of patients with CBD who underwent minimally invasive surgery at our hospital between 2013 and 2023 were retrospectively reviewed.

Results: Overall, 129 patients (89 children aged <6 years, 9 children aged between 6 and 18 years, and 21 adults) were included in this study. Children exhibited more protein plug presence and abnormal biochemical data than adults. Incidence of postoperative pancreatic fistulas was highest in the adult group (3.4%, 11%, and 33%, respectively, p < .01). In children aged <6 years, postoperative bile leakage and pancreatic fistulas occurred in 9.0% and 3.4% of patients, respectively. Multivariate logistic regression analysis revealed that the Todani IVA was associated with a decrease in postoperative bile leakage (odds ratio: -1.7; 95% confidence interval: (-3.3)-(-0.22), p = .03).

Conclusion: Adults with CBD required prolonged operative times and had more short-term complications than children with CBD. In children aged <6 years, minimally invasive surgery for CBD can be safely performed; however, a small diameter of the bile duct may be associated with bile leakage.

背景/目的:我们对成人和儿童先天性胆道扩张(CBD)的微创手术进行了评估,并分析了手术效果,尤其是儿童的手术效果:回顾性分析2013年至2023年间在我院接受微创手术的CBD患者的特征和手术效果:结果:总计129例患者(89例儿童,年龄为 岁)接受了微创手术:成人 CBD 患者比儿童 CBD 患者需要更长的手术时间和更多的短期并发症。年龄在
{"title":"Characteristics and outcomes of minimally invasive surgery for congenital biliary dilatation in children aged <6 years: Comparison between children and adults.","authors":"Yoichi Nakagawa, Hiroo Uchida, Chiyoe Shirota, Takahisa Tainaka, Satoshi Makita, Miwa Satomi, Akihiro Yasui, Yoko Kano, Daiki Kato, Takuya Maeda","doi":"10.1002/jhbp.12069","DOIUrl":"https://doi.org/10.1002/jhbp.12069","url":null,"abstract":"<p><strong>Background/purpose: </strong>We evaluated the minimally invasive surgery for congenital biliary dilatation (CBD) in adults and children and analyzed the surgical outcomes, especially in children aged <6 years.</p><p><strong>Methods: </strong>Characteristics and surgical outcomes of patients with CBD who underwent minimally invasive surgery at our hospital between 2013 and 2023 were retrospectively reviewed.</p><p><strong>Results: </strong>Overall, 129 patients (89 children aged <6 years, 9 children aged between 6 and 18 years, and 21 adults) were included in this study. Children exhibited more protein plug presence and abnormal biochemical data than adults. Incidence of postoperative pancreatic fistulas was highest in the adult group (3.4%, 11%, and 33%, respectively, p < .01). In children aged <6 years, postoperative bile leakage and pancreatic fistulas occurred in 9.0% and 3.4% of patients, respectively. Multivariate logistic regression analysis revealed that the Todani IVA was associated with a decrease in postoperative bile leakage (odds ratio: -1.7; 95% confidence interval: (-3.3)-(-0.22), p = .03).</p><p><strong>Conclusion: </strong>Adults with CBD required prolonged operative times and had more short-term complications than children with CBD. In children aged <6 years, minimally invasive surgery for CBD can be safely performed; however, a small diameter of the bile duct may be associated with bile leakage.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum trypsin as an early predictor of post-endoscopic retrograde cholangiopancreatography pancreatitis. 血清胰蛋白酶是内镜逆行胰胆管造影术后胰腺炎的早期预测指标。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-26 DOI: 10.1002/jhbp.12063
Takashi Tamura, Reiko Ashida, Tomoya Emori, Masahiro Itonoga, Yasunobu Yamashita, Keiichi Hatamaru, Yuki Kawaji, Hiromu Koutani, Takao Maekita, Masayuki Kitano

Background: Serum amylase (AMY) levels measured 2-6 h after ERCP are a predictor of post-ERCP pancreatitis (PEP). Trypsin is one of the pancreatic enzymes elevated in the development of PEP. The study assessed whether serum trypsin (TRY) can predict early-stage PEP.

Methods: This prospective study included patients who underwent ERCP from June 2022 to May 2023. TRY, AMY, serum pancreatic AMY (P-AMY), and serum lipase (LIP) levels were measured immediately after ERCP and 2 h later. The primary outcome was the diagnostic abilities of TRY levels measured immediately (0 h-TRY) and 2 h after (2 h-TRY) ERCP to predict PEP (compared with the other serum pancreatic enzymes).

Results: Of 130 patients analyzed, 18 developed PEP. The sensitivity and specificity of 0 h-TRY were 83.3% and 69.6%, respectively, and those of 2 h-TRY were 88.9% and 72.3%, respectively. The area under the curve (AUC) for 0 h-TRY was significantly higher than that for 0 h-AMY (p = .006) and 0 h-P-AMY (p = .012), whereas the AUCs for 0 h-TRY and 0 h-LIP did not differ significantly (p = .563). The AUC for 2 h-TRY for predicting PEP was significantly higher than that for 2 h-AMY (p = .025), whereas there was no significant differences between the AUCs for 2 h-TRY and 2 h-P-AMY(p = .146), or between those for 2 h-TRY and 2 h-LIP (p = .792). The median increase ratio (expressed as a ratio relative to baseline) in TRY was highest among all of serum pancreatic enzymes tested immediately after ERCP (5.35, 1.72, 1.94, and 4.44 for TRY, AMY, P-AMY, and LIP, respectively).

Conclusion: Measuring TRY immediately after ERCP is useful for the early prediction of PEP.

背景:ERCP术后2-6小时测量的血清淀粉酶(AMY)水平可预测ERCP术后胰腺炎(PEP)。胰蛋白酶是 PEP 发病过程中升高的胰腺酶之一。该研究评估了血清胰蛋白酶(TRY)能否预测早期胰腺炎:这项前瞻性研究纳入了 2022 年 6 月至 2023 年 5 月期间接受 ERCP 的患者。ERCP术后立即和2小时后测量TRY、AMY、血清胰腺AMY(P-AMY)和血清脂肪酶(LIP)水平。主要结果是ERCP后立即(0 h-TRY)和2 h后(2 h-TRY)测量的TRY水平预测PEP的诊断能力(与其他血清胰酶相比):结果:在分析的 130 例患者中,18 例出现了 PEP。0 h-TRY 的灵敏度和特异性分别为 83.3% 和 69.6%,2 h-TRY 的灵敏度和特异性分别为 88.9% 和 72.3%。0 h-TRY 的曲线下面积(AUC)明显高于 0 h-AMY (p = .006) 和 0 h-P-AMY (p = .012),而 0 h-TRY 和 0 h-LIP 的曲线下面积差异不大 (p = .563)。2 h-TRY 预测 PEP 的 AUC 明显高于 2 h-AMY (p = .025),而 2 h-TRY 和 2 h-P-AMY 的 AUC(p = .146)以及 2 h-TRY 和 2 h-LIP 的 AUC(p = .792)之间没有明显差异。在ERCP术后立即检测的所有血清胰酶中,TRY的中位增加比(以相对于基线的比率表示)最高(TRY、AMY、P-AMY和LIP分别为5.35、1.72、1.94和4.44):结论:ERCP术后立即检测TRY有助于早期预测PEP。
{"title":"Serum trypsin as an early predictor of post-endoscopic retrograde cholangiopancreatography pancreatitis.","authors":"Takashi Tamura, Reiko Ashida, Tomoya Emori, Masahiro Itonoga, Yasunobu Yamashita, Keiichi Hatamaru, Yuki Kawaji, Hiromu Koutani, Takao Maekita, Masayuki Kitano","doi":"10.1002/jhbp.12063","DOIUrl":"https://doi.org/10.1002/jhbp.12063","url":null,"abstract":"<p><strong>Background: </strong>Serum amylase (AMY) levels measured 2-6 h after ERCP are a predictor of post-ERCP pancreatitis (PEP). Trypsin is one of the pancreatic enzymes elevated in the development of PEP. The study assessed whether serum trypsin (TRY) can predict early-stage PEP.</p><p><strong>Methods: </strong>This prospective study included patients who underwent ERCP from June 2022 to May 2023. TRY, AMY, serum pancreatic AMY (P-AMY), and serum lipase (LIP) levels were measured immediately after ERCP and 2 h later. The primary outcome was the diagnostic abilities of TRY levels measured immediately (0 h-TRY) and 2 h after (2 h-TRY) ERCP to predict PEP (compared with the other serum pancreatic enzymes).</p><p><strong>Results: </strong>Of 130 patients analyzed, 18 developed PEP. The sensitivity and specificity of 0 h-TRY were 83.3% and 69.6%, respectively, and those of 2 h-TRY were 88.9% and 72.3%, respectively. The area under the curve (AUC) for 0 h-TRY was significantly higher than that for 0 h-AMY (p = .006) and 0 h-P-AMY (p = .012), whereas the AUCs for 0 h-TRY and 0 h-LIP did not differ significantly (p = .563). The AUC for 2 h-TRY for predicting PEP was significantly higher than that for 2 h-AMY (p = .025), whereas there was no significant differences between the AUCs for 2 h-TRY and 2 h-P-AMY(p = .146), or between those for 2 h-TRY and 2 h-LIP (p = .792). The median increase ratio (expressed as a ratio relative to baseline) in TRY was highest among all of serum pancreatic enzymes tested immediately after ERCP (5.35, 1.72, 1.94, and 4.44 for TRY, AMY, P-AMY, and LIP, respectively).</p><p><strong>Conclusion: </strong>Measuring TRY immediately after ERCP is useful for the early prediction of PEP.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anatomical biliary reconstruction as an ultimum refugium for selective cases-History and current state of knowledge. 将解剖胆道重建作为选择性病例的终极避难所--历史与现状。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-26 DOI: 10.1002/jhbp.12067
Jan Sevcik, Maria Stefania Massaro, Richard Palek, Vladimira Moulisova, Vaclav Liska

Reconstruction of extrahepatic bile ducts is a staple procedure of HPB surgery. The current standard for most cases is a nonanatomical bilioenteric reconstruction, a satisfactory option for the majority of patients. However, it cannot be used for a small number of selective cases (short bowel syndrome, severe abdominal adhesions), where an anatomical reconstruction with or without an interponate can be used. This review summarizes current knowledge about tissue and material usage for experimental and clinical anatomical bile duct reconstruction in the last 100 years. A Pubmed database was searched for published articles about anatomical extrahepatic bile duct reconstruction in experimental and clinical settings ranging from 1920 to 2022. To date, the truly optimal interponate material has not yet been found. However, evidence reveals important properties of such material, most importantly its biodegradability and neovascularization in the recipient's body. The role of internal bile duct stenting for anatomical reconstruction seems important for the outcome. Anatomical reconstruction of extrahepatic bile ducts is an uncommon but usable technique in unique cases when a nonanatomical reconstruction cannot be done. The optimal properties of interponate material for anatomical bile duct reconstruction have been more clarified, although further research is required.

肝外胆管重建是高胆固醇胆管炎手术的主要程序。目前大多数病例的标准是非解剖性胆肠重建,这对大多数患者来说是一个令人满意的选择。然而,它不能用于少数选择性病例(短肠综合征、严重腹腔粘连),在这些病例中,可以使用带或不带中间膜的解剖重建。本综述总结了近 100 年来有关实验和临床解剖胆管重建的组织和材料使用的现有知识。我们在 Pubmed 数据库中搜索了从 1920 年到 2022 年在实验和临床环境中发表的有关解剖性肝外胆管重建的文章。迄今为止,尚未找到真正理想的内膜材料。不过,有证据显示了这种材料的重要特性,其中最重要的是它的生物降解性和受体体内的新生血管。内胆管支架在解剖重建中的作用似乎对结果非常重要。肝外胆管解剖重建是一种不常见的技术,但在无法进行非解剖重建的特殊病例中却很实用。用于解剖胆管重建的interponate材料的最佳特性已更加明确,但仍需进一步研究。
{"title":"Anatomical biliary reconstruction as an ultimum refugium for selective cases-History and current state of knowledge.","authors":"Jan Sevcik, Maria Stefania Massaro, Richard Palek, Vladimira Moulisova, Vaclav Liska","doi":"10.1002/jhbp.12067","DOIUrl":"https://doi.org/10.1002/jhbp.12067","url":null,"abstract":"<p><p>Reconstruction of extrahepatic bile ducts is a staple procedure of HPB surgery. The current standard for most cases is a nonanatomical bilioenteric reconstruction, a satisfactory option for the majority of patients. However, it cannot be used for a small number of selective cases (short bowel syndrome, severe abdominal adhesions), where an anatomical reconstruction with or without an interponate can be used. This review summarizes current knowledge about tissue and material usage for experimental and clinical anatomical bile duct reconstruction in the last 100 years. A Pubmed database was searched for published articles about anatomical extrahepatic bile duct reconstruction in experimental and clinical settings ranging from 1920 to 2022. To date, the truly optimal interponate material has not yet been found. However, evidence reveals important properties of such material, most importantly its biodegradability and neovascularization in the recipient's body. The role of internal bile duct stenting for anatomical reconstruction seems important for the outcome. Anatomical reconstruction of extrahepatic bile ducts is an uncommon but usable technique in unique cases when a nonanatomical reconstruction cannot be done. The optimal properties of interponate material for anatomical bile duct reconstruction have been more clarified, although further research is required.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improved survival of pediatric deceased donor liver transplantation recipients after introduction of the pediatric prioritization system: Analysis of data from a Japanese national survey. 引入儿科优先系统后,儿科死亡供体肝移植受者的存活率有所提高:日本全国调查数据分析。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-19 DOI: 10.1002/jhbp.12062
Yusuke Takemura, Masahiro Shinoda, Mureo Kasahara, Seisuke Sakamoto, Etsuro Hatano, Tatsuya Okamoto, Yasuhiro Ogura, Yukihiro Sanada, Toshiharu Matsuura, Takehisa Ueno, Hideaki Obara, Yuji Soejima, Koji Umeshita, Susumu Eguchi, Yuko Kitagawa, Hiroto Egawa, Hideki Ohdan

Background: In Japan, there has never been a national analysis of pediatric deceased donor liver transplantation (pDDLT) based on donor and recipient factors. We constructed a Japanese nationwide database and assessed outcomes of pDDLT focusing on the pediatric prioritization system introduced in 2018.

Methods: We collected data on pDDLTs (<18 years) performed between 1999 and 2021 from the Japan Organ Transplant Network and Japanese Liver Transplantation Society, identified risk factors for graft survival and compared the characteristics and graft survival in pDDLTs conducted before and after the introduction of the pediatric prioritization system.

Results: Overall, 112 cases of pDDLT were included, with a 1-year graft survival rate of 86.6%. Four poor prognostic factors were identified: recipient intensive care unit stay, model for end-stage liver disease/pediatric end-stage liver disease score, donor cause of death, and donor total bilirubin. After the introduction of the system, allografts from pediatric donors were more reliably allocated to pediatric recipients and the annual number of pDDLTs increased. The 1-year graft survival rate improved significantly as did pDDLT conditions indicated by the risk factors.

Conclusions: Under the revised allocation system, opportunities for pDDLT increased, resulting in favorable recipient and donor conditions and improved survival.

背景:在日本,从未有过基于供体和受体因素的全国性小儿死亡供体肝移植(pDDLT)分析。我们构建了一个日本全国数据库,并以2018年引入的儿科优先系统为重点,评估了pDDLT的结果:我们收集了 pDDLT 的数据(结果:共纳入 112 例 pDDLT,1 年移植物存活率为 86.6%。确定了四个不良预后因素:受体重症监护室住院时间、终末期肝病模型/儿童终末期肝病评分、供体死因和供体总胆红素。引入该系统后,儿科捐献者的同种异体移植物被更可靠地分配给儿科受者,每年的 pDDLT 数量也有所增加。1年移植物存活率显著提高,风险因素显示的pDDLT情况也是如此:结论:在修订后的分配制度下,pDDLT的机会增加了,受体和供体的条件都得到了改善,存活率也提高了。
{"title":"Improved survival of pediatric deceased donor liver transplantation recipients after introduction of the pediatric prioritization system: Analysis of data from a Japanese national survey.","authors":"Yusuke Takemura, Masahiro Shinoda, Mureo Kasahara, Seisuke Sakamoto, Etsuro Hatano, Tatsuya Okamoto, Yasuhiro Ogura, Yukihiro Sanada, Toshiharu Matsuura, Takehisa Ueno, Hideaki Obara, Yuji Soejima, Koji Umeshita, Susumu Eguchi, Yuko Kitagawa, Hiroto Egawa, Hideki Ohdan","doi":"10.1002/jhbp.12062","DOIUrl":"https://doi.org/10.1002/jhbp.12062","url":null,"abstract":"<p><strong>Background: </strong>In Japan, there has never been a national analysis of pediatric deceased donor liver transplantation (pDDLT) based on donor and recipient factors. We constructed a Japanese nationwide database and assessed outcomes of pDDLT focusing on the pediatric prioritization system introduced in 2018.</p><p><strong>Methods: </strong>We collected data on pDDLTs (<18 years) performed between 1999 and 2021 from the Japan Organ Transplant Network and Japanese Liver Transplantation Society, identified risk factors for graft survival and compared the characteristics and graft survival in pDDLTs conducted before and after the introduction of the pediatric prioritization system.</p><p><strong>Results: </strong>Overall, 112 cases of pDDLT were included, with a 1-year graft survival rate of 86.6%. Four poor prognostic factors were identified: recipient intensive care unit stay, model for end-stage liver disease/pediatric end-stage liver disease score, donor cause of death, and donor total bilirubin. After the introduction of the system, allografts from pediatric donors were more reliably allocated to pediatric recipients and the annual number of pDDLTs increased. The 1-year graft survival rate improved significantly as did pDDLT conditions indicated by the risk factors.</p><p><strong>Conclusions: </strong>Under the revised allocation system, opportunities for pDDLT increased, resulting in favorable recipient and donor conditions and improved survival.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142004396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1). FOLFIRINOX 或吉西他滨加纳布紫杉醇化疗后接受转化手术的最初无法切除的胰腺癌患者的疗效:多中心回顾性队列研究(PC-CURE-1)。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-16 DOI: 10.1002/jhbp.12066
Naohiro Okano, Manabu Kawai, Makoto Ueno, Xianjun Yu, Yosuke Inoue, Shinichiro Takahashi, Wenquan Wang, Hidenori Takahashi, Yukiyasu Okamura, Soichiro Morinaga, Ippei Matsumoto, Yasuhiro Shimizu, Kazuhiro Yoshida, Tomohisa Yamamoto, Masayuki Ohtsuka, Yoshikuni Inokawa, Satoshi Nara, Jun Tamura, Satoru Shinoda, Kouji Yamamoto, Hiroki Yamaue, Junji Furuse

Background: The efficacy and safety of conversion surgery (CS) after FOLFIRINOX or gemcitabine plus nab-paclitaxel (GnP) chemotherapy in patients with initially unresectable pancreatic cancer (PC) remains unclear.

Methods: This multicenter retrospective cohort study enrolled patients, between 2014 and 2018, with initially locally advanced or metastatic PC who were considered candidates for CS following FOLFIRINOX or GnP chemotherapy. They were classified into surgery (207 patients [194 resection and 13 exploratory laparotomy only]) and continued chemotherapy (10 patients, control) groups. The primary endpoint was overall survival (OS) from the day of diagnosis of potentially curative resection on imaging studies, with an expected hazard ratio (HR) of 0.7.

Results: OS in the surgery group was longer than that in the control group (HR, 0.47; 95% confidence interval [CI]: 0.24-0.93). The median OS was 34.4 (95% CI: 27.9-43.4) and 19.8 (95% CI: 14.9-31.1) months in the surgery and control groups, respectively. The Clavien-Dindo grade ≥ IIIa postoperative complication and in-hospital mortality rates were 19.6% and 0.5%, respectively. Multivariate analysis revealed that preoperative chemotherapy duration was not associated with OS.

Conclusions: CS, following a favorable response to FOLFIRINOX or GnP chemotherapy, improved initially unresectable PC prognosis (specifically, OS), regardless of the chemotherapy duration.

背景:在FOLFIRINOX或吉西他滨+纳布-紫杉醇(GnP)化疗后,最初无法切除的胰腺癌(PC)患者接受转换手术(CS)的疗效和安全性仍不明确:这项多中心回顾性队列研究招募了2014年至2018年期间的初诊局部晚期或转移性PC患者,这些患者被认为是FOLFIRINOX或GnP化疗后CS的候选者。他们被分为手术组(207 例患者[194 例切除术和 13 例探查性开腹手术])和继续化疗组(10 例患者,对照组)。主要终点是自影像学检查诊断为潜在根治性切除术之日起的总生存期(OS),预期危险比(HR)为 0.7:手术组的 OS 长于对照组(HR,0.47;95% 置信区间 [CI]:0.24-0.93)。手术组和对照组的中位OS分别为34.4个月(95% CI:27.9-43.4)和19.8个月(95% CI:14.9-31.1)。Clavien-Dindo ≥ IIIa 级术后并发症和院内死亡率分别为 19.6% 和 0.5%。多变量分析显示,术前化疗时间与OS无关:结论:无论化疗持续时间长短如何,在对FOLFIRINOX或GnP化疗产生良好反应后进行CS治疗,可改善初始不可切除PC的预后(尤其是OS)。
{"title":"Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1).","authors":"Naohiro Okano, Manabu Kawai, Makoto Ueno, Xianjun Yu, Yosuke Inoue, Shinichiro Takahashi, Wenquan Wang, Hidenori Takahashi, Yukiyasu Okamura, Soichiro Morinaga, Ippei Matsumoto, Yasuhiro Shimizu, Kazuhiro Yoshida, Tomohisa Yamamoto, Masayuki Ohtsuka, Yoshikuni Inokawa, Satoshi Nara, Jun Tamura, Satoru Shinoda, Kouji Yamamoto, Hiroki Yamaue, Junji Furuse","doi":"10.1002/jhbp.12066","DOIUrl":"https://doi.org/10.1002/jhbp.12066","url":null,"abstract":"<p><strong>Background: </strong>The efficacy and safety of conversion surgery (CS) after FOLFIRINOX or gemcitabine plus nab-paclitaxel (GnP) chemotherapy in patients with initially unresectable pancreatic cancer (PC) remains unclear.</p><p><strong>Methods: </strong>This multicenter retrospective cohort study enrolled patients, between 2014 and 2018, with initially locally advanced or metastatic PC who were considered candidates for CS following FOLFIRINOX or GnP chemotherapy. They were classified into surgery (207 patients [194 resection and 13 exploratory laparotomy only]) and continued chemotherapy (10 patients, control) groups. The primary endpoint was overall survival (OS) from the day of diagnosis of potentially curative resection on imaging studies, with an expected hazard ratio (HR) of 0.7.</p><p><strong>Results: </strong>OS in the surgery group was longer than that in the control group (HR, 0.47; 95% confidence interval [CI]: 0.24-0.93). The median OS was 34.4 (95% CI: 27.9-43.4) and 19.8 (95% CI: 14.9-31.1) months in the surgery and control groups, respectively. The Clavien-Dindo grade ≥ IIIa postoperative complication and in-hospital mortality rates were 19.6% and 0.5%, respectively. Multivariate analysis revealed that preoperative chemotherapy duration was not associated with OS.</p><p><strong>Conclusions: </strong>CS, following a favorable response to FOLFIRINOX or GnP chemotherapy, improved initially unresectable PC prognosis (specifically, OS), regardless of the chemotherapy duration.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply letter to the editor. 给编辑的回信。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-13 DOI: 10.1002/jhbp.12060
Tianao Yan, Zheng Wang
{"title":"Reply letter to the editor.","authors":"Tianao Yan, Zheng Wang","doi":"10.1002/jhbp.12060","DOIUrl":"https://doi.org/10.1002/jhbp.12060","url":null,"abstract":"","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimizing terminology for pancreatectomy: Introducing a new notation system. 优化胰腺切除术的术语:引入新的符号系统。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-11 DOI: 10.1002/jhbp.12065
Kei Yamane, Kazuyuki Nagai, Takayuki Anazawa, Yosuke Kasai, Tomoaki Yoh, Satoshi Ogiso, Yoichiro Uchida, Takashi Ito, Takamichi Ishii, Etsuro Hatano

We introduce a novel notation system for pancreatectomy designed to provide a clear and concise representation of surgical procedures. As surgical techniques and the scope of pancreatic surgeries continue to diversify, existing communication methods among medical professionals regarding the specifics of the surgeries have proven inadequate. Our proposed notation system clearly indicates the approach (open, laparoscopic, or robot-assisted), type of surgery (e.g., pancreatoduodenectomy, distal pancreatectomy), and extent of resection and accompanying resected organs or vasculature. These elements are all recorded in this order by using abbreviations. For example, a pancreatoduodenectomy with pancreatic transection just above the SMA and combined resection of the SMV would be noted as "OPD(hb')-SMV". This new notation system allows for concise expression of the essential information on performed procedures of pancreatic resection, leading to smooth information sharing. This initiative is an essential step towards standardizing pancreatic surgery documentation on a global scale. Here, we present the development and application of this system, highlighting its potential to transform surgical communication and documentation.

我们介绍了一种新颖的胰腺切除术符号系统,旨在简明扼要地表述手术过程。随着外科技术和胰腺手术范围的不断多样化,医疗专业人员之间关于手术具体细节的现有交流方法已被证明是不够的。我们建议的记号系统清楚地标明了手术方式(开腹、腹腔镜或机器人辅助)、手术类型(如胰十二指肠切除术、远端胰腺切除术)、切除范围以及伴随切除的器官或血管。这些要素均按此顺序使用缩写进行记录。例如,胰十二指肠切除术(胰腺横断面位于 SMA 正上方)和 SMV 合并切除术将记为 "OPD(hb')-SMV"。这一新的标记系统可以简明扼要地表达胰腺切除术的基本信息,从而促进信息共享。这一举措是在全球范围内实现胰腺手术记录标准化的重要一步。在此,我们将介绍该系统的开发和应用情况,强调其改变外科交流和记录方式的潜力。
{"title":"Optimizing terminology for pancreatectomy: Introducing a new notation system.","authors":"Kei Yamane, Kazuyuki Nagai, Takayuki Anazawa, Yosuke Kasai, Tomoaki Yoh, Satoshi Ogiso, Yoichiro Uchida, Takashi Ito, Takamichi Ishii, Etsuro Hatano","doi":"10.1002/jhbp.12065","DOIUrl":"https://doi.org/10.1002/jhbp.12065","url":null,"abstract":"<p><p>We introduce a novel notation system for pancreatectomy designed to provide a clear and concise representation of surgical procedures. As surgical techniques and the scope of pancreatic surgeries continue to diversify, existing communication methods among medical professionals regarding the specifics of the surgeries have proven inadequate. Our proposed notation system clearly indicates the approach (open, laparoscopic, or robot-assisted), type of surgery (e.g., pancreatoduodenectomy, distal pancreatectomy), and extent of resection and accompanying resected organs or vasculature. These elements are all recorded in this order by using abbreviations. For example, a pancreatoduodenectomy with pancreatic transection just above the SMA and combined resection of the SMV would be noted as \"OPD(hb')-SMV\". This new notation system allows for concise expression of the essential information on performed procedures of pancreatic resection, leading to smooth information sharing. This initiative is an essential step towards standardizing pancreatic surgery documentation on a global scale. Here, we present the development and application of this system, highlighting its potential to transform surgical communication and documentation.</p>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of isolated hilar-/extrahepatic-type IgG-4-related sclerosing cholangitis can be increased by improved recognition of this condition—A Japanese multicenter analysis 提高对孤立性肝门/肝外型 IgG-4 相关硬化性胆管炎的识别能力可提高诊断率--日本多中心分析。
IF 3.2 3区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-09 DOI: 10.1002/jhbp.12053
Kensuke Kubota, Eisuke Iwasaki, Takuya Ishikawa, Masaki Kuwatani, Mamoru Takenaka, Takuji Iwashita, Atsuhiro Masuda, Tsukasa Ikeura, Akira Nakamura, Atsushi Tanaka, Hiroyuki Isayama, Yoshiki Hirooka, Kenji Hirano, Shomei Ryozawa, Takeshi Ogura, Toshio Fujisawa, Yusuke Kurita, Kazuhiro Kikuta, Nobuhiko Hayashi, Atsushi Masamune, Ichiro Yasuda

Background

Patients with isolated IgG4-related sclerosing cholangitis (IgG4-SC) often undergo unnecessary resection. The aim of this study was to validate the revised Japanese diagnostic criteria for isolated IgG-4-SC and to improve awareness about this condition in the population.

Methods

This was a Japanese retrospective multicenter study. We focused on the data and diagnostic yield obtained using the Japanese diagnostic criteria published initially in 2012 and revised later in 2020 for the diagnosis of isolated IgG4-SC.

Results

Patients with isolated IgG4-SC could be classified into two groups based on the primary location of the lesion: the hilar type (n = 40) and the extrahepatic type (n = 13). In total, 10 patients with the hilar type had undergone unnecessary resection. The revised 2020 criteria are useful for the diagnosis of extrahepatic lesions, which are not included in the 2012 criteria. The need for a steroid trial was reduced from 37.7% when the diagnosis was based on the 2012 criteria to 7.6% when the diagnosis was based on the revised 2020 criteria. The diagnostic specificity also improved from 58.5% for the 2012 criteria to 88.7% for the revised 2020 criteria.

Conclusion

Our validation of the 2020 criteria for the diagnosis of IgG4-SC could contribute to avoiding unnecessary resection in patients with isolated IgG4-SC, which can be classified into the hilar and extrahepatic types. The 2020 criteria can enhance the diagnosis rate of isolated IgG4-SC and uncover this tough-to-diagnose entity based on inclusion of the imaging findings and decrease the dependence on a steroid trial.

背景:孤立性 IgG4 相关硬化性胆管炎(IgG4-SC)患者通常会接受不必要的切除手术。本研究旨在验证日本修订后的孤立性 IgG-4-SC 诊断标准,并提高民众对该病的认识:这是一项日本多中心回顾性研究。方法:这是一项日本的回顾性多中心研究,我们重点研究了使用最初于 2012 年发布、后于 2020 年修订的日本诊断标准诊断孤立性 IgG4-SC 所获得的数据和诊断率:根据病变的原发部位,孤立性 IgG4-SC 患者可分为两组:肝门型(40 例)和肝外型(13 例)。共有 10 名肝门型患者接受了不必要的切除手术。修订后的2020年标准有助于诊断肝外病变,而2012年标准中未包括肝外病变。根据2012年标准进行诊断时,需要进行类固醇试验的比例为37.7%,而根据修订后的2020年标准进行诊断时,这一比例降至7.6%。诊断特异性也从2012年标准的58.5%提高到修订后的2020年标准的88.7%:我们对诊断 IgG4-SC 的 2020 年标准的验证有助于避免对孤立 IgG4-SC 患者进行不必要的切除术,IgG4-SC 可分为肝门型和肝外型。2020年标准可提高孤立性IgG4-SC的诊断率,并在纳入影像学检查结果的基础上发现这一难以诊断的实体,减少对类固醇试验的依赖。
{"title":"Diagnosis of isolated hilar-/extrahepatic-type IgG-4-related sclerosing cholangitis can be increased by improved recognition of this condition—A Japanese multicenter analysis","authors":"Kensuke Kubota,&nbsp;Eisuke Iwasaki,&nbsp;Takuya Ishikawa,&nbsp;Masaki Kuwatani,&nbsp;Mamoru Takenaka,&nbsp;Takuji Iwashita,&nbsp;Atsuhiro Masuda,&nbsp;Tsukasa Ikeura,&nbsp;Akira Nakamura,&nbsp;Atsushi Tanaka,&nbsp;Hiroyuki Isayama,&nbsp;Yoshiki Hirooka,&nbsp;Kenji Hirano,&nbsp;Shomei Ryozawa,&nbsp;Takeshi Ogura,&nbsp;Toshio Fujisawa,&nbsp;Yusuke Kurita,&nbsp;Kazuhiro Kikuta,&nbsp;Nobuhiko Hayashi,&nbsp;Atsushi Masamune,&nbsp;Ichiro Yasuda","doi":"10.1002/jhbp.12053","DOIUrl":"10.1002/jhbp.12053","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with isolated IgG4-related sclerosing cholangitis (IgG4-SC) often undergo unnecessary resection. The aim of this study was to validate the revised Japanese diagnostic criteria for isolated IgG-4-SC and to improve awareness about this condition in the population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a Japanese retrospective multicenter study. We focused on the data and diagnostic yield obtained using the Japanese diagnostic criteria published initially in 2012 and revised later in 2020 for the diagnosis of isolated IgG4-SC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients with isolated IgG4-SC could be classified into two groups based on the primary location of the lesion: the hilar type (<i>n</i> = 40) and the extrahepatic type (<i>n</i> = 13). In total, 10 patients with the hilar type had undergone unnecessary resection. The revised 2020 criteria are useful for the diagnosis of extrahepatic lesions, which are not included in the 2012 criteria. The need for a steroid trial was reduced from 37.7% when the diagnosis was based on the 2012 criteria to 7.6% when the diagnosis was based on the revised 2020 criteria. The diagnostic specificity also improved from 58.5% for the 2012 criteria to 88.7% for the revised 2020 criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our validation of the 2020 criteria for the diagnosis of IgG4-SC could contribute to avoiding unnecessary resection in patients with isolated IgG4-SC, which can be classified into the hilar and extrahepatic types. The 2020 criteria can enhance the diagnosis rate of isolated IgG4-SC and uncover this tough-to-diagnose entity based on inclusion of the imaging findings and decrease the dependence on a steroid trial.</p>\u0000 </section>\u0000 </div>","PeriodicalId":16056,"journal":{"name":"Journal of Hepato‐Biliary‐Pancreatic Sciences","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141912926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Hepato‐Biliary‐Pancreatic Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1